Traumatic Brain Injury in the Long-COVID Era
Major determinants of the biological background or reserve, such as age, biological sex, comorbidities (diabetes, hypertension, obesity, etc.), and medications (e.g., anticoagulants), are known to affect outcome after traumatic brain injury (TBI). With the unparalleled data richness of coronavirus d...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mary Ann Liebert
2024-11-01
|
| Series: | Neurotrauma Reports |
| Subjects: | |
| Online Access: | https://www.liebertpub.com/doi/10.1089/neur.2023.0067 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321838573780992 |
|---|---|
| author | Denes V. Agoston |
| author_facet | Denes V. Agoston |
| author_sort | Denes V. Agoston |
| collection | DOAJ |
| description | Major determinants of the biological background or reserve, such as age, biological sex, comorbidities (diabetes, hypertension, obesity, etc.), and medications (e.g., anticoagulants), are known to affect outcome after traumatic brain injury (TBI). With the unparalleled data richness of coronavirus disease 2019 (COVID-19; ∼375,000 and counting!) as well as the chronic form, long-COVID, also called post-acute sequelae SARS-CoV-2 infection (PASC), publications (∼30,000 and counting) covering virtually every aspect of the diseases, pathomechanisms, biomarkers, disease phases, symptomatology, etc., have provided a unique opportunity to better understand and appreciate the holistic nature of diseases, interconnectivity between organ systems, and importance of biological background in modifying disease trajectories and affecting outcomes. Such a holistic approach is badly needed to better understand TBI-induced conditions in their totality. Here, I briefly review what is known about long-COVID/PASC, its underlying—suspected—pathologies, the pathobiological changes induced by TBI, in other words, the TBI endophenotypes, discuss the intersection of long-COVID/PASC and TBI-induced pathobiologies, and how by considering some of the known factors affecting the person's biological background and the inclusion of mechanistic molecular biomarkers can help to improve the clinical management of TBI patients. |
| format | Article |
| id | doaj-art-2b385c29093e4db3b07b46e256ca48d2 |
| institution | Kabale University |
| issn | 2689-288X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Mary Ann Liebert |
| record_format | Article |
| series | Neurotrauma Reports |
| spelling | doaj-art-2b385c29093e4db3b07b46e256ca48d22025-08-20T03:49:37ZengMary Ann LiebertNeurotrauma Reports2689-288X2024-11-0151819410.1089/neur.2023.0067Traumatic Brain Injury in the Long-COVID EraDenes V. Agoston0Department of Anatomy, Physiology, and Genetics, School of Medicine, Uniformed Services University, Bethesda, Maryland, USA.Major determinants of the biological background or reserve, such as age, biological sex, comorbidities (diabetes, hypertension, obesity, etc.), and medications (e.g., anticoagulants), are known to affect outcome after traumatic brain injury (TBI). With the unparalleled data richness of coronavirus disease 2019 (COVID-19; ∼375,000 and counting!) as well as the chronic form, long-COVID, also called post-acute sequelae SARS-CoV-2 infection (PASC), publications (∼30,000 and counting) covering virtually every aspect of the diseases, pathomechanisms, biomarkers, disease phases, symptomatology, etc., have provided a unique opportunity to better understand and appreciate the holistic nature of diseases, interconnectivity between organ systems, and importance of biological background in modifying disease trajectories and affecting outcomes. Such a holistic approach is badly needed to better understand TBI-induced conditions in their totality. Here, I briefly review what is known about long-COVID/PASC, its underlying—suspected—pathologies, the pathobiological changes induced by TBI, in other words, the TBI endophenotypes, discuss the intersection of long-COVID/PASC and TBI-induced pathobiologies, and how by considering some of the known factors affecting the person's biological background and the inclusion of mechanistic molecular biomarkers can help to improve the clinical management of TBI patients.https://www.liebertpub.com/doi/10.1089/neur.2023.0067biological reservecomorbiditiestraumatic brain injury |
| spellingShingle | Denes V. Agoston Traumatic Brain Injury in the Long-COVID Era Neurotrauma Reports biological reserve comorbidities traumatic brain injury |
| title | Traumatic Brain Injury in the Long-COVID Era |
| title_full | Traumatic Brain Injury in the Long-COVID Era |
| title_fullStr | Traumatic Brain Injury in the Long-COVID Era |
| title_full_unstemmed | Traumatic Brain Injury in the Long-COVID Era |
| title_short | Traumatic Brain Injury in the Long-COVID Era |
| title_sort | traumatic brain injury in the long covid era |
| topic | biological reserve comorbidities traumatic brain injury |
| url | https://www.liebertpub.com/doi/10.1089/neur.2023.0067 |
| work_keys_str_mv | AT denesvagoston traumaticbraininjuryinthelongcovidera |